Pimozide is an antipsychotic used to manage debilitating motor and phonic tics in patients with Tourette's Disorder. Although the precise mechanism of action is unknown, blockade of postsynaptic dopamine receptors has been postulated.
- Mechanism
- Curator reviewed
The ability of pimozide to suppress motor and phonic tics in Tourette's Disorder is thought to be primarily a function of its dopaminergic blocking activity. Pimozide binds and inhibits the dopamine D2 receptor in the CNS.
- Primary indication
- Used for the suppression of motor and phonic tics in patients with Tourette's Disorder who have failed to respond satisfactorily to standard treatment.Curator reviewed · 2 structured indications
- Formula / weight
- C28H29F2N3O · 461.5462 g/mol (avg)
- First approval
- Canada, 1999 · United States, 1990
- Code names
- MCN-JR-6238 · R-623 · R-6238
- Brand names
Resolves to
Clinical / RWD
Structure
InChIKey
YVUQSNJEYSNKRX-UHFFFAOYSA-NSMILESFC1=CC=C(C=C1)C(CCCN1CCC(CC1)N1C(=O)NC2=CC=CC=C12)C1=CC=C(F)C=C1Transporters
What you can answer from here — as of September 23, 2026
6Protein targetsEach mapped to UniProt, with action and pharmacological actionListed above
1TransporterSubstrate / inhibitor direction, not just membershipListed above
Which drugs share a target with Pimozide, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account